Exit strategies of pharmaceutical multinational companies from Portugal and the successful implementation of new Portuguese companies

Utilize este identificador para referenciar este registo: http://hdl.handle.net/10362/11793

Registo completo

Campo DC	Valor	Idioma
dc.contributor.advisor	Barros, Pedro Pita	-
dc.contributor.author	Pinheiro, Catarina Quelhas dos Santos da Costa	-
dc.date.accessioned	2014-03-21T19:30:16Z	-
dc.date.available	2014-03-21T19:30:16Z	-
dc.date.issued	2014-01	-
dc.identifier.uri	http://hdl.handle.net/10362/11793	-
dc.description	A Work Project, presented as part of the requirements for the Award of a Masters Degree in Management from the NOVA – School of Business and Economics	por
dc.description.abstract	In 2001 and 2004, two multinational companies (MNC) of the pharmaceutical industry, respectively Bayer and Janssen, left its manufacture operations in Portugal. From its exit, other two Portuguese small and medium enterprises (SME) were born: Bluepharma and Lusomedicamenta. These companies have been highly successful due to the representativeness of exports, contract-manufacturing and generic production. This report intents to study the exit of the MNC and the implementation of the Portuguese SMEs.	por
dc.language.iso	eng	por
dc.publisher	NSBE - UNL	por
dc.rights	openAccess	por
dc.subject	Pharmaceutical industry	por
dc.subject	Portuguese SME	por
dc.subject	Exports	por
dc.subject	Contract manufacturing	por
dc.subject	Generics	por
dc.title	Exit strategies of pharmaceutical multinational companies from Portugal and the successful implementation of new Portuguese companies	por
dc.type	masterThesis	por
dc.peerreviewed	no	por
dc.identifier.tid	201529513	-
Aparece nas colecções:	NSBE: Nova SBE - MA Dissertations

Ficheiros deste registo:

Ficheiro	Descrição	Tamanho	Formato
Pinheiro_2014.pdf		409,06 kB	Adobe PDF	Ver/Abrir